{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T08:30:17Z","timestamp":1780734617550,"version":"3.54.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bayer Hispania SL"},{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-03850-z","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T19:03:10Z","timestamp":1739818990000},"page":"3307-3324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical advances and practice updates in genitourinary cancers: a 2024 review from the multidisciplinary Spanish \u2018Cambados annual meeting\u2019"],"prefix":"10.1007","volume":"27","author":[{"given":"Ignacio","family":"Pel\u00e1ez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00edn","family":"L\u00e1zaro-Quintela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"P\u00e9rez-Fentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Esteban-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"\u00c1lvarez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"\u00c1lvarez Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urbano","family":"Anido-Herranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Azpitarte Raposeiras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel Maximino","family":"Castro-Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ovidio","family":"Fern\u00e1ndez Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Fern\u00e1ndez N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Folgar-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carme","family":"Garc\u00eda Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ar\u00e1nzazu","family":"Gonz\u00e1lez-del-Alba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"M\u00e9ndez-Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurea","family":"Molina D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio Rodr\u00edguez","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4973-3198","authenticated-orcid":false,"given":"Sergio","family":"V\u00e1zquez-Est\u00e9vez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"3850_CR1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"D Tilki","year":"2024","unstructured":"Tilki D, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II\u20142024 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2024;86:164\u201382. https:\/\/doi.org\/10.1016\/j.eururo.2024.04.010.","journal-title":"Eur Urol"},{"key":"3850_CR2","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","volume":"31","author":"C Parker","year":"2020","unstructured":"Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:1119\u201334. https:\/\/doi.org\/10.1016\/j.annonc.2020.06.011.","journal-title":"Ann Oncol"},{"key":"3850_CR3","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/s0140-6736(20)31553-1","volume":"396","author":"CC Parker","year":"2020","unstructured":"Parker CC, Clarke NW, Cook AD, Kynaston HG, Petersen PM, Catton C, et al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet. 2020;396:1413\u201321. https:\/\/doi.org\/10.1016\/s0140-6736(20)31553-1.","journal-title":"Lancet"},{"key":"3850_CR4","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/s1470-2045(20)30456-3","volume":"21","author":"A Kneebone","year":"2020","unstructured":"Kneebone A, Fraser-Browne C, Duchesne GM, Fisher R, Frydenberg M, Herschtal A, et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol. 2020;21:1331\u201340. https:\/\/doi.org\/10.1016\/s1470-2045(20)30456-3.","journal-title":"Lancet Oncol"},{"key":"3850_CR5","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/s1470-2045(20)30454-x","volume":"21","author":"P Sargos","year":"2020","unstructured":"Sargos P, Chabaud S, Latorzeff I, Magn\u00e9 N, Benyoucef A, Supiot S, et al. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol. 2020;21:1341\u201352. https:\/\/doi.org\/10.1016\/s1470-2045(20)30454-x.","journal-title":"Lancet Oncol"},{"issue":"7","key":"3850_CR6","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.annonc.2024.03.010","volume":"35","author":"CC Parker","year":"2024","unstructured":"Parker CC, Petersen PM, Cook AD, Clarke NW, Catton C, Cross WR, et al. Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047). Ann Oncol. 2024;35(7):656\u201366. https:\/\/doi.org\/10.1016\/j.annonc.2024.03.010.","journal-title":"Ann Oncol"},{"key":"3850_CR7","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.eururo.2024.07.026","volume":"86","author":"CC Parker","year":"2024","unstructured":"Parker CC, Clarke NW, Cook AD, Petersen PM, Catton CN, Cross WR, et al. Randomised trial of no, short-term, or long-term androgen deprivation therapy with postoperative radiotherapy after radical prostatectomy: results from the three-way comparison of RADICALS-HD (NCT00541047). Eur Urol. 2024;86:422\u201330. https:\/\/doi.org\/10.1016\/j.eururo.2024.07.026.","journal-title":"Eur Urol"},{"key":"3850_CR8","doi-asserted-by":"publisher","first-page":"S1428","DOI":"10.1016\/j.annonc.2022.08.067","volume":"33","author":"S Burdett","year":"2022","unstructured":"Burdett S, Fisher D, Parker C, Sydes M, Pommier P, Sargos P, et al. LBA64 duration of androgen suppression with post-operative radiotherapy (DADSPORT): a collaborative meta-analysis of aggregate data. Ann Oncol. 2022;33:S1428\u20139. https:\/\/doi.org\/10.1016\/j.annonc.2022.08.067.","journal-title":"Ann Oncol"},{"key":"3850_CR9","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","volume":"389","author":"SJ Freedland","year":"2023","unstructured":"Freedland SJ, de Almeida LM, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med. 2023;389:1453\u201365. https:\/\/doi.org\/10.1056\/NEJMoa2303974.","journal-title":"N Engl J Med"},{"key":"3850_CR10","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377:338\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1702900.","journal-title":"N Engl J Med"},{"key":"3850_CR11","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352\u201360. https:\/\/doi.org\/10.1056\/NEJMoa1704174.","journal-title":"N Engl J Med"},{"key":"3850_CR12","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37:2974\u201386. https:\/\/doi.org\/10.1200\/JCO.19.00799.","journal-title":"J Clin Oncol"},{"key":"3850_CR13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381:121\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1903835.","journal-title":"N Engl J Med"},{"key":"3850_CR14","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1200\/JCO.22.00193","volume":"40","author":"AJ Armstrong","year":"2022","unstructured":"Armstrong AJ, Azad AA, Iguchi T, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2022;40:1616\u201322. https:\/\/doi.org\/10.1200\/JCO.22.00193.","journal-title":"J Clin Oncol"},{"key":"3850_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, de Santana P, Gomes AJ, Given R, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381:13\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1903307.","journal-title":"N Engl J Med"},{"key":"3850_CR16","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1200\/jco.20.03488","volume":"39","author":"KN Chi","year":"2021","unstructured":"Chi KN, Chowdhury S, Bjartell A, Chung BH, de Santana P, Gomes AJ, Given R, et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol. 2021;39:2294\u2013303. https:\/\/doi.org\/10.1200\/jco.20.03488.","journal-title":"J Clin Oncol"},{"key":"3850_CR17","doi-asserted-by":"publisher","first-page":"5000","DOI":"10.1200\/JCO.2021.39.15_suppl.5000","volume":"39","author":"K Fizazi","year":"2021","unstructured":"Fizazi K, Maldonado X, Foulon S, Roubaud G, McDermott RS, Flechon A, et al. A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and\/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): first results of PEACE-1. J Clin Oncol. 2021;39:5000. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.5000.","journal-title":"J Clin Oncol"},{"key":"3850_CR18","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Eng J Med. 2022;386:1132\u201342. https:\/\/doi.org\/10.1056\/NEJMoa2119115.","journal-title":"N Eng J Med"},{"key":"3850_CR19","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1200\/JCO-24-01798","volume":"86","author":"F Saad","year":"2024","unstructured":"Saad F, Hussain MHA, Tombal B, Fizazi K, Sternberg CN, Crawford ED, et al. Deep and durable prostate-specific antigen response to darolutamide with androgen deprivation therapy and docetaxel, and association with clinical outcomes for patients with high- or low-volume metastatic hormone-sensitive prostate cancer: analyses of the randomized phase 3 ARASENS study. Eur Urol. 2024;86:329\u201339. https:\/\/doi.org\/10.1200\/JCO-24-01798.","journal-title":"Eur Urol"},{"key":"3850_CR20","doi-asserted-by":"crossref","unstructured":"Saad F, Vjaters E, Shore N, Olmos D, Xing N, Pereira de Santana Gomes AJ, et al. Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial. J Clin Oncol. 2024:JCO21798","DOI":"10.1016\/j.annonc.2024.08.2311"},{"key":"3850_CR21","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1503747.","journal-title":"N Engl J Med"},{"key":"3850_CR22","doi-asserted-by":"publisher","unstructured":"Shore ND, Preston MA, Gregg JR, Salami SS, Ross A, Bruno A, et al. Darolutamide plus androgen-deprivation therapy (ADT) versus ADT in metastatic hormone-sensitive prostate cancer: Open-label single-arm study with an external control arm (ARASEC). J Clin Oncol. 2023;41:TPS297. https:\/\/doi.org\/10.1200\/JCO.2023.41.6_suppl.TPS297","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS297"},{"key":"3850_CR23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.eururo.2024.03.018","volume":"86","author":"S Roy","year":"2024","unstructured":"Roy S, Fervaha G, Spratt DE, Sun Y, Kishan AU, Loblaw A, et al. Prostate radiotherapy in low-volume metastatic hormone-sensitive prostate cancer: a network meta-analysis. Eur Urol. 2024;86:10\u20137. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.018.","journal-title":"Eur Urol"},{"key":"3850_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.eururo.2023.10.012","volume":"85","author":"M Miszczyk","year":"2024","unstructured":"Miszczyk M, Rajwa P, Yanagisawa T, Nowicka Z, Shim SR, Laukhtina E, et al. The efficacy and safety of metastasis-directed therapy in patients with prostate cancer: a systematic review and meta-analysis of prospective studies. Eur Urol. 2024;85:125\u201338. https:\/\/doi.org\/10.1016\/j.eururo.2023.10.012.","journal-title":"Eur Urol"},{"key":"3850_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1200\/JCO.2024.42.4_suppl.19","volume":"42","author":"MHA Hussain","year":"2024","unstructured":"Hussain MHA, Kocherginsky M, Agarwal N, Adra N, Zhang J, Paller CJ, et al. BRCAAway: a randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm). J Clin Oncol. 2024;42:19. https:\/\/doi.org\/10.1200\/JCO.2024.42.4_suppl.19.","journal-title":"J Clin Oncol"},{"key":"3850_CR26","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024;404:1227\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(24)01653-2.","journal-title":"Lancet"},{"key":"3850_CR27","doi-asserted-by":"publisher","first-page":"S1254","DOI":"10.1016\/j.annonc.2024.08.2307","volume":"35","author":"S Gillessen","year":"2024","unstructured":"Gillessen S, Choudhury A, Saad F, Gallardo E, Soares A, Loriot Y, et al. LBA1 a randomized multicenter open label phase III trial comparing enzalutamide vs a combination of radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): first results of EORTC-GUCG 1333\/PEACE-3. Ann Oncol. 2024;35:S1254. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2307.","journal-title":"Ann Oncol"},{"key":"3850_CR28","unstructured":"UroToday. UroToday. Conference highlights: ESMO 2024: Invited Discussant\u2014EORTC-GUCG 1333\/PEACE-32024. 2024. https:\/\/www.urotoday.com\/conference-highlights\/esmo-2024\/esmo-2024-prostate-cancer\/154816-esmo-2024-invited-discussant-eortc-gucg-1333-peace-3.html. Accessed 02 Dec 2024"},{"key":"3850_CR29","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/s1470-2045(18)30860-x","volume":"20","author":"M Smith","year":"2019","unstructured":"Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:408\u201319. https:\/\/doi.org\/10.1016\/s1470-2045(18)30860-x.","journal-title":"Lancet Oncol"},{"key":"3850_CR30","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","volume":"35","author":"T Powles","year":"2024","unstructured":"Powles T, Albiges L, Bex A, Comperat E, Gr\u00fcnwald V, Kanesvaran R, et al. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35:692\u2013706. https:\/\/doi.org\/10.1016\/j.annonc.2024.05.537.","journal-title":"Ann Oncol"},{"key":"3850_CR31","unstructured":"EAU Guidelines on Renal Cell Carcinoma. Edn. presented at the EAU Annual Congress Paris 2024. ISBN 978\u201394\u201392671\u201323\u201332024. https:\/\/uroweb.org\/guidelines\/renal-cell-carcinoma Accessed 02 Dec 2024"},{"key":"3850_CR32","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMoa2106391","volume":"385","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2021;385:683\u201394. https:\/\/doi.org\/10.1056\/NEJMoa2106391.","journal-title":"N Engl J Med"},{"key":"3850_CR33","doi-asserted-by":"publisher","unstructured":"Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, et al. Overall survival with adjuvant pembrolizumab in renal-cell carcinoma. N Eng J Med. 2024;390:1359\u201371. https:\/\/doi.org\/10.1056\/NEJMoa2312695","DOI":"10.1056\/NEJMoa2312695"},{"key":"3850_CR34","doi-asserted-by":"publisher","unstructured":"Motzer RJ, Bex A, Russo P, Tomita Y, Cutuli H, Rojas C, et al (2024) Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: results from Part B of the randomized, phase 3 CheckMate 914 trial. J Clin Oncol 42:LBA358. https:\/\/doi.org\/10.1200\/JCO.2024.42.4_suppl.LBA358","DOI":"10.1200\/JCO.2024.42.4_suppl.LBA358"},{"key":"3850_CR35","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/S1470-2045(24)00211-0","volume":"25","author":"ME Allaf","year":"2024","unstructured":"Allaf ME, Kim SE, Master V, McDermott DF, Harshman LC, Cole SM, et al. Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study. Lancet Oncol. 2024;25:1038\u201352. https:\/\/doi.org\/10.1016\/S1470-2045(24)00211-0.","journal-title":"Lancet Oncol"},{"key":"3850_CR36","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/S0140-6736(23)00913-3","volume":"402","author":"CW Ryan","year":"2023","unstructured":"Ryan CW, Tangen CM, Heath EI, Stein MN, Meng MV, Alva AS, et al. Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2023;402:1043\u201351. https:\/\/doi.org\/10.1016\/S0140-6736(23)00913-3.","journal-title":"Lancet"},{"key":"3850_CR37","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.eururo.2024.05.012","volume":"86","author":"PN Lara Jr","year":"2024","unstructured":"Lara PN Jr, Tangen C, Heath EI, Gulati S, Stein MN, Meng M, et al. Adjuvant everolimus in patients with completely resected, very high-risk renal cell carcinoma of clear cell histology: results from the phase 3 placebo-controlled SWOG S0931 (EVEREST) trial. Eur Urol. 2024;86:258\u201364. https:\/\/doi.org\/10.1016\/j.eururo.2024.05.012.","journal-title":"Eur Urol"},{"key":"3850_CR38","doi-asserted-by":"publisher","unstructured":"Y Yan XQ, Ye MJ, Zou Q, Chen P, He ZS, Wu B, et al. Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study. Ann Oncol. 2024;35:190\u2013199. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.3108","DOI":"10.1016\/j.annonc.2023.09.3108"},{"key":"3850_CR39","doi-asserted-by":"publisher","first-page":"S1263","DOI":"10.1016\/j.annonc.2024.08.2319","volume":"35","author":"X Sheng","year":"2024","unstructured":"Sheng X, Shen P, Qu W, Wang Z, Li Y, Ren X, et al. LBA76 anlotinib in combined with anti-PD-L1 antibody benmelstobart (TQB2450) versus sunitinib in first-line treatment of advanced renal cell carcinoma (RCC): a randomized, open-label, phase III study (ETER100). Ann Oncol. 2024;35:S1263\u20134. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2319.","journal-title":"Ann Oncol"},{"key":"3850_CR40","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"J Motzer Robert","year":"2019","unstructured":"Motzer Robert J, Penkov K, Haanen J, Rini B, Albiges L, Campbell Matthew T, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Eng J Med. 2019;380:1103\u201315. https:\/\/doi.org\/10.1056\/NEJMoa1816047.","journal-title":"N Eng J Med"},{"key":"3850_CR41","doi-asserted-by":"publisher","first-page":"4508","DOI":"10.1200\/JCO.2024.42.16_suppl.4508","volume":"42","author":"RJ Motzer","year":"2024","unstructured":"Motzer RJ, Penkov K, Uemura H, Campbell MT, Kollmannsberger CK, Lee J-L, et al. Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial. J Clin Oncol. 2024;42:4508. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.4508.","journal-title":"J Clin Oncol"},{"key":"3850_CR42","doi-asserted-by":"publisher","first-page":"S1263","DOI":"10.1016\/j.annonc.2024.08.2318","volume":"35","author":"L Bergmann","year":"2024","unstructured":"Bergmann L, Ahrens M, Albiges L, Gross Goupil M, Boleti E, Gravis G, et al. LBA75 prospective randomised phase-II trial of ipilimumab\/nivolumab versus standard of care in non-clear cell renal cell cancer: results of the SUNNIFORECAST trial. Ann Oncol. 2024;35:S1263. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2318.","journal-title":"Ann Oncol"},{"key":"3850_CR43","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S1470-2045(23)00276-0","volume":"24","author":"L Albiges","year":"2023","unstructured":"Albiges L, Gurney H, Atduev V, Suarez C, Climent MA, Pook D, et al. Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2023;24:881\u201391. https:\/\/doi.org\/10.1016\/S1470-2045(23)00276-0.","journal-title":"Lancet Oncol"},{"key":"3850_CR44","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1200\/JCO.2024.42.4_suppl.2","volume":"42","author":"MH Voss","year":"2024","unstructured":"Voss MH, Gurney H, Atduev V, Su\u00e1rez C, Climent M\u00c1, Pook DW, et al. First-line pembrolizumab plus lenvatinib for non\u2013clear cell renal carcinomas (nccRCC): Extended follow-up of the phase 2 KEYNOTE-B61 study. J Clin Oncol. 2024;42:2. https:\/\/doi.org\/10.1200\/JCO.2024.42.4_suppl.2.","journal-title":"J Clin Oncol"},{"key":"3850_CR45","doi-asserted-by":"publisher","first-page":"S1015","DOI":"10.1016\/j.annonc.2024.08.1786","volume":"35","author":"L Albiges","year":"2024","unstructured":"Albiges L, Powles TB, Sharma A, Venugopal B, Bedke J, Borkowetz A, et al. 1693P CaboPoint: final results from a phase II study of cabozantinib after checkpoint inhibitor (CPI) combinations in patients with advanced renal cell carcinoma (aRCC). Ann Oncol. 2024;35:S1015. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.1786.","journal-title":"Ann Oncol"},{"key":"3850_CR46","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/S0140-6736(24)01758-6","volume":"404","author":"TK Choueiri","year":"2024","unstructured":"Choueiri TK, Albiges L, Barth\u00e9l\u00e9my P, Iacovelli R, Emambux S, Molina-Cerrillo J, et al. Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 study. Lancet. 2024;404:1309\u201320. https:\/\/doi.org\/10.1016\/S0140-6736(24)01758-6.","journal-title":"Lancet"},{"key":"3850_CR47","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJMoa2313906","volume":"391","author":"TK Choueiri","year":"2024","unstructured":"Choueiri TK, Powles T, Peltola K, de Velasco G, Burotto M, Suarez C, et al. Belzutifan versus everolimus for advanced renal-cell carcinoma. N Engl J Med. 2024;391:710\u20131.","journal-title":"N Engl J Med"},{"key":"3850_CR48","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","volume":"33","author":"T Powles","year":"2022","unstructured":"Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, et al. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:244\u201358. https:\/\/doi.org\/10.1016\/j.annonc.2021.11.012.","journal-title":"Ann Oncol"},{"key":"3850_CR49","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","volume":"391","author":"T Powles","year":"2024","unstructured":"Powles T, Catto JWF, Galsky MD, Al-Ahmadie H, Meeks JJ, Nishiyama H, et al. Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. N Engl J Med. 2024;391:1773\u201386. https:\/\/doi.org\/10.1056\/NEJMoa2408154.","journal-title":"N Engl J Med"},{"key":"3850_CR50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401726","author":"AB Apolo","year":"2024","unstructured":"Apolo AB, Ballman KV, Sonpavde G, Berg S, Kim WY, Parikh R, et al. Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2401726.","journal-title":"N Engl J Med"},{"key":"3850_CR51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00340","author":"MD Galsky","year":"2024","unstructured":"Galsky MD, Witjes JA, Gschwend JE, Milowsky MI, Schenker M, Valderrama BP, et al. Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from checkmate. J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/JCO.24.00340.","journal-title":"J Clin Oncol"},{"key":"3850_CR52","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/jco.21.02051","volume":"40","author":"C Pfister","year":"2022","unstructured":"Pfister C, Gravis G, Fl\u00e9chon A, Chevreau C, Mahammedi H, Laguerre B, et al. Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial. J Clin Oncol. 2022;40:2013\u201322. https:\/\/doi.org\/10.1200\/jco.21.02051.","journal-title":"J Clin Oncol"},{"key":"3850_CR53","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S1470-2045(23)00587-9","volume":"25","author":"C Pfister","year":"2024","unstructured":"Pfister C, Gravis G, Flechon A, Chevreau C, Mahammedi H, Laguerre B, et al. Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study. Lancet Oncol. 2024;25:255\u201364. https:\/\/doi.org\/10.1016\/S1470-2045(23)00587-9.","journal-title":"Lancet Oncol"},{"key":"3850_CR54","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383:1218\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2002788.","journal-title":"N Engl J Med"},{"key":"3850_CR55","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024;390:875\u201388. https:\/\/doi.org\/10.1056\/NEJMoa2312117.","journal-title":"N Engl J Med"},{"key":"3850_CR56","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","volume":"389","author":"MS van der Heijden","year":"2023","unstructured":"van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, et al. Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma. N Engl J Med. 2023;389:1778\u201389. https:\/\/doi.org\/10.1056\/NEJMoa2309863.","journal-title":"N Engl J Med"},{"key":"3850_CR57","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","volume":"35","author":"T Powles","year":"2024","unstructured":"Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, et al. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma. Ann Oncol. 2024;35:485\u201390. https:\/\/doi.org\/10.1016\/j.annonc.2024.03.001.","journal-title":"Ann Oncol"},{"key":"3850_CR58","unstructured":"EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Edn. Presented at the EAU Annual Congress Paris 2024. ISBN 978\u201394\u201392671\u201323\u20133.2024. https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-Guidelines-on-Muscle-Invasive-and-Metastatic-Bladder-Cancer-2024.pdf Accessed 02 Dec 2024"},{"key":"3850_CR59","doi-asserted-by":"publisher","first-page":"4509","DOI":"10.1200\/JCO.2024.42.16_suppl.4509","volume":"42","author":"MD Galsky","year":"2024","unstructured":"Galsky MD, Sonpavde GP, Powles T, Claps M, Burotto M, Schenker M, et al. Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node\u2013only metastatic urothelial carcinoma from the CheckMate 901 trial. J Clin Oncol. 2024;42:4509. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.4509.","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1007\/s12094-025-03911-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000}}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-03850-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-03850-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-03850-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T05:48:42Z","timestamp":1757137722000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-03850-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":59,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["3850"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-03850-z","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s12094-025-03911-3","asserted-by":"object"}]},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,17]]},"assertion":[{"value":"13 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12094-025-03911-3","URL":"https:\/\/doi.org\/10.1007\/s12094-025-03911-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Carlos \u00c1lvarez-Fern\u00e1ndez reports having received consulting fees, payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Merck, Pfizer, Astra-Zeneca, and Bayer; and support for attending meetings and\/or travel from Ipsen, Roche, and Pfizer. Pablo \u00c1lvarez Rodr\u00edguez reports having received consulting fees, payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Merck, Ipsen,\u00a0Novartis, MSD, and Roche; support for attending meetings and\/or travel from MSD, Ipsen, Gilead, Pierre-Fabre and Lilly; and having participated in a Data Safety Monitoring Board or Advisory Board for Pierre-Fabre. Urbano Anido-Herranz reports having received consulting fees, payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Merck, Ipsen,\u00a0MSD, Roche, Astra-Zeneca, Janssen, Bayer,\u00a0BMS and Novartis; support for attending meetings and\/or travel from MSD, Ipsen, Novartis, Roche, Rovi and BMS; and having participated in Advisory Board for Pfizer. Cristina Azpitarte Raposeiras reports having received honoraria for presentations, speakers\u00b4bureaus from BMS, Merck, Takeda, Janssen, AstraZeneca. Roche, Lilly, Bayer, MSD and Ipsen; support for attending meetings and\/or travel from Roche, MSD, Lilly, Ipsen, AstraZeneca, Takeda and Bayer. \u00c1ngel Maximino Castro-Iglesias reports no conflicts of interest. Emilio Esteban-Gonz\u00e1lez reports financial support to participate, travel, and attend the 2024 Cambados annual meeting. Ovidio Fern\u00e1ndez Calvo reports having received consulting fees, payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Astellas, Bayer Bristol-Myers Squibb, Ipsen, Novartis and Roche; support for attending meetings and\/or travel from Astellas, Bristol-Myers Squibb and Ipsen; and having participated in a Data Safety Monitoring Board or Advisory Board for Astellas, Bristol-Myers Squibb, Eisai, Merck, and Pfizer. Natalia Fern\u00e1ndez N\u00fa\u00f1ez reports having received consulting fees, payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Pfizer, Ipsen, Roche, BMS, Bayer, Astra Z\u00e9neca, MSD, and Lilly; support for attending meetings and\/or travel from Pfizer, Ipsen, Roche, BMS, Bayer, Astra Z\u00e9neca, MSD, and Lilly; and having participated in a Data Safety Monitoring Board or Advisory Board for Pfizer. Alicia Folgar-Torres reports having received consulting fees, payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Johnson &Johnson, Ipsen; support for attending meetings and\/or travel from Astellas, Janssen, Kyowa Kirin and GP-Pharm. Enrique Gallardo reports having received consulting fees, payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Astellas, Janssen, Sanofi, Bayer, Ipsen, Pfizer, Roche, BMS, Rovi, Daiichi Sankyo, Leo Pharma, Eisai, Boehringer Ingelheim, Merck, EUSA Pharma, Lilly, Advanced Accelerator Applications and GSK; support for attending meetings and\/or travel from Astellas, Janssen, Sanofi, BMS, Bayer, Ipsen, Roche, Novartis, Pierre Fabre, Pfizer, Eisai, AstraZeneca and Leo Pharma; and having participated in a Data Safety Monitoring Board or Advisory Board for Sanofi, Janssen, Astellas, Bayer, Ipsen, Pfizer, Roche, Novartis, Eisai, Recordati, BMS, MSD, AstraZeneca, Merck, Rovi, Daiichi Sankyo, Techdow, Lilly, GSK and Advanced Accelerator Applications. Carme Garc\u00eda Lorenzo reports having received payment or honoraria for speaker, travel, or accommodation for attending meetings from Merck, Ipsen, Bayer, Astellas, BMS,\u00a0MSD, Janssen. Ar\u00e1nzazu Gonz\u00e1lez del Alba has received research funding from Astellas, travel grants from Astellas, Jansen, Sanofi, BMS, Roche, Pfizer, MSD, Bayer, Astra Zeneca and Ipsen and honoraria for speaker engagements, advisory boards and continuous medical education from Janssen, Astellas, Sanofi, Bayer, Roche, Ipsen, BMS, MSD, Pfizer, Eusa Pharma, Recordati, Merck, Eisai, Novartis, AAA and AstraZeneca. Mart\u00edn L\u00e1zaro-Quintela reports having received consulting fees, payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Merck, Ipsen,\u00a0MSD, Lilly, Roche, Astra-Zeneca, Janssen, Regeneron, Bayer,\u00a0BMS and Novartis; support for attending meetings and\/or travel from MSD, Ipsen, Takeda, Roche and BMS; and having participated in a Data Safety Monitoring Board or Advisory Board for Pfizer, Merck, Astellas, Bayer, Telix, BMS and Novartis. Mar\u00eda Jos\u00e9 M\u00e9ndez-Vidal reports having received consulting fees, payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Merck, Ipsen,\u00a0MSD, Astra-Zeneca, Janssen, Bayer,\u00a0BMS and Novartis; support for attending meetings and\/or travel from, Ipsen, Jassen, Roche and BMS; and having participated in an Advisory Board for Ipsen, Astra Zeneca, Janssen, Pfizer, Astellas, Telix, BMS and Novartis. Aurea Molina D\u00edaz reports having received consulting fees, payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Merck, Ipsen,\u00a0MSD, Lilly, Roche, Astra-Zeneca, Janssen, Pierre Fabre, Pharmamar, Novocure, Bayer,\u00a0BMS and Novartis; support for attending meetings and\/or travel from MSD, Ipsen, Takeda, Roche and BMS; and having participated in Advisory Board for Pfizer, Merck, Astellas, Pierre Fabre and Deciphera Pharmaceuticals. Ignacio Pel\u00e1ez Fern\u00e1ndez reports having received consulting fees, payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Astellas, Bayer, Merck, Ipsen. BMS, Roche, Pfizer, Astra Zeneca and Novartis. Support for attending meetings and\/or travel from, Ipsen, Pfizer and Merck; and having participated in an Advisory Board for Ipsen, Astra Zeneca, Pfizer and Astellas. Daniel P\u00e9rez-Fentes reports having received consulting fees, payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Astellas, Johnson &Johnson, Bayer, Accord; support for attending meetings and\/or travel from Bayer, Johnson & Johnson; and having participated in a Data Safety Monitoring Board or Advisory Board for Astellas, Bayer, Johnson & Johnson and Recordati. Ignacio Rodr\u00edguez reports having received consulting fees, payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing or educational events from Astellas, Johnson & Johnson, Bayer and Sanofi; and having participated in Advisory Board for Astellas, Bayer, Johnson & Johnson and GSK. Sergio V\u00e1zquez Est\u00e9vez\u00a0reports having received consulting fees,\u00a0payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from Merck, Ipsen,\u00a0MSD, Astra-Zeneca, Janssen, Bayer,\u00a0BMS and Novartis; support for attending meetings and\/or travel from, Ipsen, Bayer and\u00a0Roche; and having participated in an Advisory Board for Ipsen, Astra Zeneca, Janssen, Pfizer, Astellas, BMS, Bayer and Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}